Empagliflozin and Combination Therapy
- سال انتشار: 1398
- محل انتشار: پنجمین همایش بین المللی و هفتمین همایش سراسری تازه های غدد و متابولیسم
- کد COI اختصاصی: ICEMU05_033
- زبان مقاله: انگلیسی
- تعداد مشاهده: 514
نویسندگان
M.D., Ph.D. Professor of Medicine, Physiology and Biophysics Departments of Medicine and Biochemistry, Case Western Reserve University University Hospitals of Cleveland and VA Medical Center, Cleveland, U.S.A
چکیده
Members of the SGLT2 inhibitor family of medications are fairly new therapeutics that are approved world-wide for glycemic management of patients with type 2 diabetes (T2DM). In addition to their glycaemia-lowering actions, they also have remarkable effects in preventing recurrent CVD events in people with established CVD and some of the members have shown positive effects on renal outcomes. A continuing challenge in the management of patients with T2DM is the large number of medications that are needed on a daily basis to control the various aspects of this metabolic disorder and the difficulty faced by patients to adhere to the treatment plan. It has been known for years that combining 2 or 3 medications into one pill (poly-pill idea) improves adherence, efficacy, and outcomes in a variety of disorders. In this lecture, data on the mode of action of SGLT2 inhibitors will be presented, and the efficacy and safety of empagliflozin will be reviewed. Then, results of studies using combination therapy (in a fixed dose single tablet form) of empagliflozin plus metformin and empagliflozin plus linagliptin in drug naïve patients with T2DM will be summarized. Finally, results of a study on use of empagliflozin plus linagliptin in patients poorly controlled on metformin alone will be presented. The evidence shows that the combination therapy presents advantages for improved outcomes.کلیدواژه ها
مقالات مرتبط جدید
اطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.